Hitachi High-Tech of Japan and Roche, a Swiss company, have decided to continue their alliance for a minimum of ten more years. By combining the businesses’ experience and proven track records in engineering, manufacturing and diagnostics innovation, the extended contract protects the two businesses’ enduring alliance.

Together, the businesses have made important contributions to innovation that have opened the door for leading in-vitro diagnostic products. From automating immunology to transforming clinical laboratories with the first multi-channel analyzer ever made, the partnership has produced ground-breaking inventions that have helped healthcare systems and labs meet delivery problems and provide patients with the care they require.

Roche and Hitachi High-Tech intend to launch new innovations later in 2024, such as the Cobas c 703 and Cobas ISE Neo analytical units for Cobas Pro integrated solutions, to boost lab testing capacity and offer timely and accurate diagnosis to millions of patients worldwide.

Another exciting milestone will be reached by the end of the year with the launch of the new Cobas Mass Spec solution, which incorporates fully-automated mass spectrometry into everyday lab operations. As a result, more individuals worldwide will have access to the gold standard technology for a wider range of clinical applications.

“Hitachi High-Tech and Roche have worked together to expand in the field of in-vitro diagnostics by boldly pursuing innovations. The renewal of this agreement demonstrates both companies’ commitment to the future of the global diagnostics market. We look forward to continuing to work together to further expand the utility of in-vitro diagnostics in healthcare,” said Taku Sakazume, Executive Officer, Head of Diagnostic System Business, Hitachi High-Tech Corporation.

These kinds of innovations are changing the way and places where diagnostics are provided, as well as contributing to the resilience and sustainability of health systems around the globe.